Khosla Impact

Aktiia is a company focused on providing continuous and accurate blood pressure monitoring to address hypertension, a prevalent chronic condition affecting over 1.4 billion people globally. Founded on two decades of research, Aktiia has developed a unique tool that combines optical sensors with clinically validated software algorithms to measure blood pressure at the wrist. This innovative approach enables individuals to gain insights into their blood pressure patterns and understand the underlying causes of hypertension. By delivering personalized, continuous, and medical-grade blood pressure and heart rate data, Aktiia aims to enhance patient care and empower patients, researchers, and clinicians. The company's mission is to improve the accessibility, accuracy, and actionability of blood pressure management, ultimately contributing to better health outcomes and reducing the significant mortality associated with high blood pressure.

HealthifyMe is a fitness application that supports users in achieving their health and weight loss objectives through digital platforms, including computers and smartphones. Launched in 2012 and based in Bangalore, India, the application allows users to track calories, nutrition, and fitness activities while monitoring their weight and overall health. It also enables users to set personalized health goals and access expert advice from nutritionists and fitness trainers. The platform features an artificial intelligence-powered fitness coach that uses automated analytics to help users manage their dietary intake and receive tailored online fitness consultations. Through its comprehensive tools and expert guidance, HealthifyMe aims to enhance individual wellness and promote healthier lifestyles.

Even is a health tech company that provides comprehensive health coverage services through a subscription model. By partnering with leading hospitals, it offers unlimited access to diagnostics, consultations, and substantial hospitalization coverage for a fixed monthly fee. Even streamlines the healthcare experience with a claimless reimbursement process, directly transferring funds to partner hospitals on behalf of its members. This approach allows individuals to efficiently address their long-term health needs while simplifying the often complex healthcare payment process.

Synex Medical is a company focused on advancing health monitoring technology through non-invasive blood testing. It has developed a portable device that utilizes a miniaturized magnetic resonance system to measure blood metabolites without the need for skin penetration. This innovative approach employs only magnets and radio waves, ensuring no adverse health effects for users. By accurately measuring critical metabolites such as glucose, lactate, and ketones, Synex Medical's technology empowers individuals to monitor their health proactively and make informed decisions about their well-being.

Neurode is a healthcare technology company developing a non-invasive wearable device, a headset, designed to enhance cognitive function for individuals with neurological conditions such as ADHD. The device aims to treat and monitor ADHD symptoms by employing non-invasive electrical stimulation to balance brain activity, while a paired app tracks improvements and facilitates communication with clinicians.

Inflammatix is a molecular diagnostics company based in Burlingame, California, founded in 2016. It specializes in developing rapid tests that analyze the immune system to address significant clinical and public health issues. The company's initial focus is on creating tests for acute bacterial and viral infections, as well as sepsis, utilizing patent-pending biomarkers exclusively licensed from Stanford University. Inflammatix also builds a diagnostics pipeline based on host response, which includes tests for tropical infections, autoimmune diseases, transplant rejection, and other conditions.

Viome Life Sciences, established in 2016 and headquartered in Bellevue, Washington, specializes in providing comprehensive health insights through its proprietary at-home clinical-grade tests. The company analyzes RNA from stool samples, along with other bodily fluids, to determine the makeup of microbial communities, offering personalized recommendations for diet and lifestyle based on the results. Viome's services aim to empower individuals to track their microbiome health, mitochondrial health, cellular health, and biological age, ultimately aiding in the prevention and reversal of chronic diseases. The company operates as a subsidiary of BlueDot LLC and sells its products through distributors and online channels.

Even is a health tech company that provides comprehensive health coverage services through a subscription model. By partnering with leading hospitals, it offers unlimited access to diagnostics, consultations, and substantial hospitalization coverage for a fixed monthly fee. Even streamlines the healthcare experience with a claimless reimbursement process, directly transferring funds to partner hospitals on behalf of its members. This approach allows individuals to efficiently address their long-term health needs while simplifying the often complex healthcare payment process.

Q Bio, Inc., established in 2015, develops a comprehensive health assessment platform that combines advanced non-invasive imaging, genetic testing, vital signs, and medical history to provide a snapshot of an individual's health. The company's flagship product, Q BioVault, aggregates and summarizes an individual's entire medical history, identifying and tracking significant health changes. Q Bio's interdisciplinary team, based in San Carlos, California, comprises experts in applied math, computational physics, electrical engineering, genetics, and radiology. Backed by prominent venture capital firms, the company aims to empower healthcare professionals with proactive, data-driven insights to improve patient outcomes.

Karius, Inc. is a life sciences company based in Redwood City, California, with an additional office in Menlo Park. Founded in 2014, Karius specializes in generating genomic insights for infectious diseases through its innovative Karius Test. This non-invasive blood test utilizes sequencing of microbial cell-free DNA to identify and quantify a wide range of pathogens, including bacteria, DNA viruses, fungi, and parasites. The Karius Test is particularly useful in the diagnosis of complicated pneumonia, infections in immunocompromised patients, and endocarditis, enabling clinicians to make rapid and informed treatment decisions. Karius operates a CLIA-certified and CAP-accredited laboratory, providing high-complexity clinical laboratory testing and offering services for pathogen biomarker detection aimed at biopharmaceutical companies. The company is dedicated to advancing the understanding and management of infectious diseases, striving for a future where these conditions pose less of a threat to human health.

Limbic is a London-based company founded in 2017 that specializes in developing innovative solutions for mental healthcare. The company creates an AI-enabled platform and software development kit (SDK) that measures heart rates through wearable devices, such as the Apple Watch, to assess users' emotional states. By leveraging machine learning, Limbic aims to enhance psychological therapy by providing insights into patients' mental health conditions. Additionally, the company offers medical devices that facilitate referrals and clinical assessments, thereby supporting mental health professionals in delivering effective therapies. Limbic is committed to addressing the growing mental health crisis by providing scalable solutions that improve the well-being of individuals.

Aktiia is a company focused on providing continuous and accurate blood pressure monitoring to address hypertension, a prevalent chronic condition affecting over 1.4 billion people globally. Founded on two decades of research, Aktiia has developed a unique tool that combines optical sensors with clinically validated software algorithms to measure blood pressure at the wrist. This innovative approach enables individuals to gain insights into their blood pressure patterns and understand the underlying causes of hypertension. By delivering personalized, continuous, and medical-grade blood pressure and heart rate data, Aktiia aims to enhance patient care and empower patients, researchers, and clinicians. The company's mission is to improve the accessibility, accuracy, and actionability of blood pressure management, ultimately contributing to better health outcomes and reducing the significant mortality associated with high blood pressure.

Encellin Inc., established in 2016, is a biotechnology company based in San Francisco, California. It specializes in developing innovative thin-film cell encapsulation devices for cell-based therapeutics, aiming to improve the lives of patients with chronic diseases initially focusing on Type 1 diabetes. The company's technology enables encapsulated cells to function as smart molecular factories, providing potential therapeutic solutions.

Vivodyne is a biotechnology company that specializes in developing an advanced automated robotic system aimed at discovering innovative drugs and cellular therapies. The company has created a microfluidic bioengineering platform that focuses on single-cell 4D phenomics, allowing for a detailed exploration of biological complexities. Its technology enables the cultivation of highly realistic human tissue models for drug discovery, incorporating an integrated confocal microscope. This platform not only accelerates the drug development process but also allows researchers to formulate tunable mixtures of compounds and cell therapies. Through its unique approach, Vivodyne seeks to advance the understanding of human health and facilitate the creation of effective treatments for various diseases.

Viome Life Sciences, established in 2016 and headquartered in Bellevue, Washington, specializes in providing comprehensive health insights through its proprietary at-home clinical-grade tests. The company analyzes RNA from stool samples, along with other bodily fluids, to determine the makeup of microbial communities, offering personalized recommendations for diet and lifestyle based on the results. Viome's services aim to empower individuals to track their microbiome health, mitochondrial health, cellular health, and biological age, ultimately aiding in the prevention and reversal of chronic diseases. The company operates as a subsidiary of BlueDot LLC and sells its products through distributors and online channels.

SiPhox Health, based in Cambridge, Massachusetts, specializes in designing and manufacturing innovative diagnostic solutions. The company develops next-generation diagnostics infrastructure, including at-home test kits and central lab systems. Their flagship product is a disposable biosensor cartridge that assesses 17 blood biomarkers, providing insights into inflammation, hormonal health, metabolic fitness, and cardiovascular health. SiPhox Health's platform merges biochemistry, photonic chip technology, integrated photonics, electronics, and microfluidics to enable sensitive readouts of immunoassays and nucleic acid tests, facilitating point-of-need and at-home diagnostics.

SiPhox Health, based in Cambridge, Massachusetts, specializes in designing and manufacturing innovative diagnostic solutions. The company develops next-generation diagnostics infrastructure, including at-home test kits and central lab systems. Their flagship product is a disposable biosensor cartridge that assesses 17 blood biomarkers, providing insights into inflammation, hormonal health, metabolic fitness, and cardiovascular health. SiPhox Health's platform merges biochemistry, photonic chip technology, integrated photonics, electronics, and microfluidics to enable sensitive readouts of immunoassays and nucleic acid tests, facilitating point-of-need and at-home diagnostics.

HealthifyMe is a fitness application that supports users in achieving their health and weight loss objectives through digital platforms, including computers and smartphones. Launched in 2012 and based in Bangalore, India, the application allows users to track calories, nutrition, and fitness activities while monitoring their weight and overall health. It also enables users to set personalized health goals and access expert advice from nutritionists and fitness trainers. The platform features an artificial intelligence-powered fitness coach that uses automated analytics to help users manage their dietary intake and receive tailored online fitness consultations. Through its comprehensive tools and expert guidance, HealthifyMe aims to enhance individual wellness and promote healthier lifestyles.

Gather Health is an international healthcare technology company dedicated to empowering chronic disease patients to enhance their health. The company develops mobile and cloud-based healthcare applications that utilize cutting-edge medical and behavioral research to motivate and educate patients. By connecting physicians, patients, their families, and communities, Gather Health aims to provide continuous and holistic care that leads to improved health outcomes. The rise in chronic diseases such as obesity, diabetes, and hypertension has created a pressing need for effective patient care solutions, especially given the shortage of healthcare providers. Gather Health's flagship product, the Gather Health Diabetes platform, is currently utilized by physicians and patients in various cities across Hong Kong and India, including Mumbai and Bangalore, demonstrating positive health outcomes for users. Headquartered in Hong Kong, with additional offices in Beijing, New York, and India, the company boasts a diverse team of clinicians, health experts, interaction designers, and engineers experienced in the global healthcare landscape.

Even is a health tech company that provides comprehensive health coverage services through a subscription model. By partnering with leading hospitals, it offers unlimited access to diagnostics, consultations, and substantial hospitalization coverage for a fixed monthly fee. Even streamlines the healthcare experience with a claimless reimbursement process, directly transferring funds to partner hospitals on behalf of its members. This approach allows individuals to efficiently address their long-term health needs while simplifying the often complex healthcare payment process.

Viome Life Sciences, established in 2016 and headquartered in Bellevue, Washington, specializes in providing comprehensive health insights through its proprietary at-home clinical-grade tests. The company analyzes RNA from stool samples, along with other bodily fluids, to determine the makeup of microbial communities, offering personalized recommendations for diet and lifestyle based on the results. Viome's services aim to empower individuals to track their microbiome health, mitochondrial health, cellular health, and biological age, ultimately aiding in the prevention and reversal of chronic diseases. The company operates as a subsidiary of BlueDot LLC and sells its products through distributors and online channels.

Carver Biosciences is a biotechnology company specializing in the development of CRISPR/Cas13-based antiviral therapies. The company's innovative approach focuses on utilizing the Cas13 technology to target and destroy RNA viruses at the molecular level, particularly respiratory viruses. By eliminating these viruses, Carver aims to prevent their replication, thereby providing a therapeutic option that complements existing vaccinations and antiviral treatments. This technology is designed to help patients manage infections more effectively, potentially arresting disease progression and offering alternative treatment solutions in the face of viral challenges.

AliveCor, Inc. specializes in developing digital medical-grade electrocardiograms, enabling users to monitor their heart health through mobile technology. The company's flagship product, KardiaMobile, is a personal mobile EKG device that provides instant detection of common heart arrhythmias, along with features for blood pressure and weight tracking, as well as storage for recorded EKGs. Additionally, AliveCor offers KardiaMobile 6L, a six-lead EKG device that allows patients to share detailed EKG readings with healthcare providers. The company also operates KardiaCare, a digital health subscription service that empowers users to manage their heart health conveniently at home. Founded in 2010 and incorporated in 2011, AliveCor is headquartered in Mountain View, California, and is recognized for its innovative contributions to cardiac care through the integration of machine learning techniques.

Ultima Genomics is a biotechnology company established in 2016 and headquartered in Newark, California. It specializes in genome-scale sequencing technology, focusing on providing analytical services to various enterprises. By employing an open substrate, Ultima Genomics creates a vast, low-cost reaction surface that facilitates billions of reads without relying on expensive flow cells or complex fluidic systems. The company utilizes specialized sequencing hardware combined with machine learning techniques to ensure reproducible and accurate results. This innovative approach enables clients to obtain genomic reports at scale, enhancing the speed and efficiency of sequencing while significantly reducing costs. Ultima Genomics aims to harness the potential of genomic information to drive advancements in biology and improve human health.

Oobli is a food company focused on developing innovative protein sweeteners derived from exotic plants. These unique sweeteners offer a delicious taste while significantly reducing calories, making them a healthier alternative to traditional sugars. Produced through fermentation, Oobli's sweeteners have no glycemic impact and do not influence the gut microbiome, allowing consumers to enjoy sweetness without concerns related to blood sugar, insulin, or weight management. The company has successfully obtained regulatory approvals, including FDA "no questions" letters and GRAS status for multiple protein sources, which positions it as a leader in the healthy sweetener market. By transforming flavors, Oobli aims to enhance everyday food experiences while promoting better health outcomes for its users.

COR helps you implement globally-proven healthy lifestyle practices, then shows you a totally new type of data about how your body responds. Optimize your lifestyle and discover the impact of different daily customs with precise, science-based self-knowledge.

Scipher Medicine Corporation is a biotechnology company based in Waltham, Massachusetts, that specializes in precision medicine for patients with autoimmune and cardiovascular diseases. The company has developed a molecular technology platform that utilizes blood samples to analyze RNA and predict patient responses to drug therapies. Its primary offerings include PrismDx tests, which identify patients who may not respond to certain medications, ensuring they can be prescribed alternative treatments. Notably, the PrismRA test assesses patients with rheumatoid arthritis to determine their likelihood of responding to anti-TNF therapies, while PrismUC serves a similar purpose for patients with ulcerative colitis. By focusing on the underlying disease biology rather than just symptoms, Scipher Medicine aims to optimize treatment from the outset, potentially reducing the healthcare costs associated with ineffective therapies. Established in 2013 and rebranded in 2015, Scipher Medicine is committed to transforming drug prescription practices and advancing drug development through its innovative approach.

Cellino is focused on developing a scalable, automated biomanufacturing system aimed at producing personalized cell therapies. The company's innovative platform leverages AI-guided laser editing to generate autologous induced pluripotent stem cells (iPSCs) efficiently and at scale. By utilizing image-guided machine learning, single-cell laser processing, and robotics, Cellino seeks to make advanced, potentially curative treatments accessible for a range of chronic degenerative diseases, including vision loss and Parkinson's disease. The company's mission is to transform healthcare by enabling personalized therapies that can significantly improve patient outcomes and overall health.

Fountain Therapeutics, established in 2018 and headquartered in San Francisco, specializes in developing treatments for age-related diseases using cellular models and an AI-based platform for target discovery. The company aims to recreate aging's complex hallmarks in lab dishes, combining this model with artificial intelligence and computer vision to identify novel targets unbiasedly.

Viome Life Sciences, established in 2016 and headquartered in Bellevue, Washington, specializes in providing comprehensive health insights through its proprietary at-home clinical-grade tests. The company analyzes RNA from stool samples, along with other bodily fluids, to determine the makeup of microbial communities, offering personalized recommendations for diet and lifestyle based on the results. Viome's services aim to empower individuals to track their microbiome health, mitochondrial health, cellular health, and biological age, ultimately aiding in the prevention and reversal of chronic diseases. The company operates as a subsidiary of BlueDot LLC and sells its products through distributors and online channels.

House Rx is a health technology platform focused on improving affordability and patient access to specialty medications.

Encellin Inc., established in 2016, is a biotechnology company based in San Francisco, California. It specializes in developing innovative thin-film cell encapsulation devices for cell-based therapeutics, aiming to improve the lives of patients with chronic diseases initially focusing on Type 1 diabetes. The company's technology enables encapsulated cells to function as smart molecular factories, providing potential therapeutic solutions.

Deep Genomics Inc. is an artificial intelligence therapeutics company based in Toronto, Canada, founded in 2014. The company focuses on developing individualized genetic medicines by utilizing AI systems to enhance various aspects of drug discovery and development, such as target discovery, lead optimization, toxicity assessment, and innovative trial design. Deep Genomics specializes in creating oligonucleotide therapies that address the genetic underpinnings of diseases at the RNA and DNA levels, targeting rare metabolic, ophthalmologic, and neurodegenerative disorders. Its AI-powered platform decodes the complexities of RNA biology, enabling the identification of novel therapeutic targets and mechanisms that traditional methods cannot access. This innovative approach positions Deep Genomics at the forefront of revolutionizing drug discovery, ultimately aiming to provide new treatments for currently untreatable diseases.

Even is a health tech company that provides comprehensive health coverage services through a subscription model. By partnering with leading hospitals, it offers unlimited access to diagnostics, consultations, and substantial hospitalization coverage for a fixed monthly fee. Even streamlines the healthcare experience with a claimless reimbursement process, directly transferring funds to partner hospitals on behalf of its members. This approach allows individuals to efficiently address their long-term health needs while simplifying the often complex healthcare payment process.

HealthifyMe is a fitness application that supports users in achieving their health and weight loss objectives through digital platforms, including computers and smartphones. Launched in 2012 and based in Bangalore, India, the application allows users to track calories, nutrition, and fitness activities while monitoring their weight and overall health. It also enables users to set personalized health goals and access expert advice from nutritionists and fitness trainers. The platform features an artificial intelligence-powered fitness coach that uses automated analytics to help users manage their dietary intake and receive tailored online fitness consultations. Through its comprehensive tools and expert guidance, HealthifyMe aims to enhance individual wellness and promote healthier lifestyles.

Ellipsis Health, Inc. is a technology company based in San Francisco, California, founded in 2013. It specializes in developing innovative analytics solutions that integrate patient speech and clinical data to assess mental health and well-being. By utilizing artificial intelligence, Ellipsis Health aims to enhance behavioral health outcomes through the analysis of natural conversation. The company has created a platform that generates clinical-grade assessments of anxiety and depression severity, as well as sub-clinical evaluations of stress levels. This technology enables healthcare providers to continuously screen their patient populations, offering a cost-effective method to identify conditions such as depression and ensure patients receive timely support.

Hello Heart Inc., established in 2013 and headquartered in Redwood City, California, specializes in developing digital health solutions. Its flagship product is Hello Heart, a mobile application designed to empower individuals to manage their heart health effectively. The app enables users to track their blood pressure and weight, providing real-time personalized tips based on clinical guidelines. Employers can also utilize this platform to proactively manage employee health risks associated with high blood pressure, fostering behavior change and preventing serious health issues.

Rightway is a technology and services company focused on transforming the healthcare experience for clients and members. Specializing in care navigation and pharmacy benefit management (PBM) solutions, Rightway aims to reduce healthcare spending by guiding members to optimal care and therapies. The company's innovative approach incorporates clinical guidance and advocacy, ensuring that members receive the best possible healthcare at lower costs. Rightway’s modern care navigation technology offers efficient clinical support, while its unique PBM model drives prescriptions to the lowest net costs, minimizing overall expenses. By combining these services, Rightway strives to create a seamless and cost-effective healthcare journey for individuals and organizations alike.

Scipher Medicine Corporation is a biotechnology company based in Waltham, Massachusetts, that specializes in precision medicine for patients with autoimmune and cardiovascular diseases. The company has developed a molecular technology platform that utilizes blood samples to analyze RNA and predict patient responses to drug therapies. Its primary offerings include PrismDx tests, which identify patients who may not respond to certain medications, ensuring they can be prescribed alternative treatments. Notably, the PrismRA test assesses patients with rheumatoid arthritis to determine their likelihood of responding to anti-TNF therapies, while PrismUC serves a similar purpose for patients with ulcerative colitis. By focusing on the underlying disease biology rather than just symptoms, Scipher Medicine aims to optimize treatment from the outset, potentially reducing the healthcare costs associated with ineffective therapies. Established in 2013 and rebranded in 2015, Scipher Medicine is committed to transforming drug prescription practices and advancing drug development through its innovative approach.

Inflammatix is a molecular diagnostics company based in Burlingame, California, founded in 2016. It specializes in developing rapid tests that analyze the immune system to address significant clinical and public health issues. The company's initial focus is on creating tests for acute bacterial and viral infections, as well as sepsis, utilizing patent-pending biomarkers exclusively licensed from Stanford University. Inflammatix also builds a diagnostics pipeline based on host response, which includes tests for tropical infections, autoimmune diseases, transplant rejection, and other conditions.

Cellino is focused on developing a scalable, automated biomanufacturing system aimed at producing personalized cell therapies. The company's innovative platform leverages AI-guided laser editing to generate autologous induced pluripotent stem cells (iPSCs) efficiently and at scale. By utilizing image-guided machine learning, single-cell laser processing, and robotics, Cellino seeks to make advanced, potentially curative treatments accessible for a range of chronic degenerative diseases, including vision loss and Parkinson's disease. The company's mission is to transform healthcare by enabling personalized therapies that can significantly improve patient outcomes and overall health.

Lumiata Inc. is a company specializing in predictive health analytics tailored for risk-bearing organizations. Founded in 2013 and based in San Mateo, California, Lumiata utilizes a medical graph that systematically organizes and analyzes a vast array of data points, facilitating real-time predictive analytics for hospital networks and insurance carriers. This technology provides insights into symptoms, diagnoses, procedures, and medications, allowing healthcare providers to enhance patient care efficiency. The company's flagship product, The Lumiata Risk Matrix, offers personalized predictions regarding individual health changes and their timeline, grounded in a robust chain of medical reasoning. Lumiata's platform leverages over 120 million patient records, integrating advanced machine learning tools and pre-trained models to support various applications such as underwriting and care management. By combining big data with clinical expertise, Lumiata empowers healthcare organizations to manage risks and costs effectively while ensuring privacy for individual members.

Curai Health is a virtual care company founded in 2017 by Neal Khosla and Xavier Amatriain, headquartered in Palo Alto. The company specializes in providing affordable primary care through a chat-based interface that integrates artificial intelligence with human clinicians. This approach leverages advanced machine learning tools to streamline patient interactions and enhance diagnostic accuracy. By creating a responsive learning healthcare system, Curai Health aims to make high-quality primary care accessible to everyone, reducing the overall cost of care delivery. The service is available directly to consumers and can also be accessed through enterprise partnerships, emphasizing its commitment to improving healthcare accessibility and affordability.

AliveCor, Inc. specializes in developing digital medical-grade electrocardiograms, enabling users to monitor their heart health through mobile technology. The company's flagship product, KardiaMobile, is a personal mobile EKG device that provides instant detection of common heart arrhythmias, along with features for blood pressure and weight tracking, as well as storage for recorded EKGs. Additionally, AliveCor offers KardiaMobile 6L, a six-lead EKG device that allows patients to share detailed EKG readings with healthcare providers. The company also operates KardiaCare, a digital health subscription service that empowers users to manage their heart health conveniently at home. Founded in 2010 and incorporated in 2011, AliveCor is headquartered in Mountain View, California, and is recognized for its innovative contributions to cardiac care through the integration of machine learning techniques.

SiPhox Health, based in Cambridge, Massachusetts, specializes in designing and manufacturing innovative diagnostic solutions. The company develops next-generation diagnostics infrastructure, including at-home test kits and central lab systems. Their flagship product is a disposable biosensor cartridge that assesses 17 blood biomarkers, providing insights into inflammation, hormonal health, metabolic fitness, and cardiovascular health. SiPhox Health's platform merges biochemistry, photonic chip technology, integrated photonics, electronics, and microfluidics to enable sensitive readouts of immunoassays and nucleic acid tests, facilitating point-of-need and at-home diagnostics.

Oobli is a food company focused on developing innovative protein sweeteners derived from exotic plants. These unique sweeteners offer a delicious taste while significantly reducing calories, making them a healthier alternative to traditional sugars. Produced through fermentation, Oobli's sweeteners have no glycemic impact and do not influence the gut microbiome, allowing consumers to enjoy sweetness without concerns related to blood sugar, insulin, or weight management. The company has successfully obtained regulatory approvals, including FDA "no questions" letters and GRAS status for multiple protein sources, which positions it as a leader in the healthy sweetener market. By transforming flavors, Oobli aims to enhance everyday food experiences while promoting better health outcomes for its users.

Menten AI, established in 2018 with headquarters in San Francisco and a satellite office in Toronto, is an early-stage biotech company specializing in drug discovery. It leverages machine learning and quantum computing to develop novel protein-based drugs and enzymes for pharmaceutical and chemical industries. Menten AI's core offering is a proprietary protein design algorithm tailored for current and near-term quantum computers, enabling efficient exploration of protein structures for therapeutic applications, such as oncology and neurodegeneration, and industrial enzyme development.

Siren Care, Inc. is a San Francisco-based company founded in 2015 that specializes in wearable health technology for diabetic health tracking. The company has developed an innovative product, the Siren diabetic socks, which continuously monitor foot temperature—an early indicator of potential injuries that can lead to ulcers. This smart sock system allows for real-time tracking and sends temperature data to healthcare providers, enabling them to detect early signs of inflammation and other complications in at-risk patients. By engaging with healthcare providers and payers, Siren Care aims to improve the management of chronic diseases, particularly diabetes, and enhance patient outcomes through its comprehensive Siren Diabetic Foot Program.

Yes Health Inc. is a company that specializes in developing mobile application software focused on nutrition, fitness, and diabetes prevention. Established in 2015 and based in Mill Valley, California, Yes Health provides a program that delivers personalized advice and encouragement to support a healthy lifestyle. The program features a team of physicians, health coaches, and engineers who collaborate to create an engaging, cost-effective solution aimed at preventing the onset of diabetes and managing symptoms for those already diagnosed. By emphasizing the development of lasting healthy habits, Yes Health empowers individuals to take control of their health in an enjoyable manner, ultimately striving to combat diabetes.

E25Bio Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2018, that focuses on developing rapid diagnostic tests for epidemic fever viruses. The company designs paper-based diagnostic systems and kits that facilitate the detection of viruses such as dengue, chikungunya, and Zika. E25Bio's innovative platform enables multiplexed testing that quickly identifies viral antigens during infections, allowing for real-time data reporting through a mobile application. This capability supports epidemiologic predictions and disease mapping, empowering governments and health organizations to respond effectively to outbreaks and manage public health crises. Through its commitment to fast, mobile testing solutions, E25Bio aims to prevent severe health outcomes associated with viral epidemics.

Karius, Inc. is a life sciences company based in Redwood City, California, with an additional office in Menlo Park. Founded in 2014, Karius specializes in generating genomic insights for infectious diseases through its innovative Karius Test. This non-invasive blood test utilizes sequencing of microbial cell-free DNA to identify and quantify a wide range of pathogens, including bacteria, DNA viruses, fungi, and parasites. The Karius Test is particularly useful in the diagnosis of complicated pneumonia, infections in immunocompromised patients, and endocarditis, enabling clinicians to make rapid and informed treatment decisions. Karius operates a CLIA-certified and CAP-accredited laboratory, providing high-complexity clinical laboratory testing and offering services for pathogen biomarker detection aimed at biopharmaceutical companies. The company is dedicated to advancing the understanding and management of infectious diseases, striving for a future where these conditions pose less of a threat to human health.

Q Bio, Inc., established in 2015, develops a comprehensive health assessment platform that combines advanced non-invasive imaging, genetic testing, vital signs, and medical history to provide a snapshot of an individual's health. The company's flagship product, Q BioVault, aggregates and summarizes an individual's entire medical history, identifying and tracking significant health changes. Q Bio's interdisciplinary team, based in San Carlos, California, comprises experts in applied math, computational physics, electrical engineering, genetics, and radiology. Backed by prominent venture capital firms, the company aims to empower healthcare professionals with proactive, data-driven insights to improve patient outcomes.

Fountain Therapeutics, established in 2018 and headquartered in San Francisco, specializes in developing treatments for age-related diseases using cellular models and an AI-based platform for target discovery. The company aims to recreate aging's complex hallmarks in lab dishes, combining this model with artificial intelligence and computer vision to identify novel targets unbiasedly.

Inflammatix is a molecular diagnostics company based in Burlingame, California, founded in 2016. It specializes in developing rapid tests that analyze the immune system to address significant clinical and public health issues. The company's initial focus is on creating tests for acute bacterial and viral infections, as well as sepsis, utilizing patent-pending biomarkers exclusively licensed from Stanford University. Inflammatix also builds a diagnostics pipeline based on host response, which includes tests for tropical infections, autoimmune diseases, transplant rejection, and other conditions.

Deep Genomics Inc. is an artificial intelligence therapeutics company based in Toronto, Canada, founded in 2014. The company focuses on developing individualized genetic medicines by utilizing AI systems to enhance various aspects of drug discovery and development, such as target discovery, lead optimization, toxicity assessment, and innovative trial design. Deep Genomics specializes in creating oligonucleotide therapies that address the genetic underpinnings of diseases at the RNA and DNA levels, targeting rare metabolic, ophthalmologic, and neurodegenerative disorders. Its AI-powered platform decodes the complexities of RNA biology, enabling the identification of novel therapeutic targets and mechanisms that traditional methods cannot access. This innovative approach positions Deep Genomics at the forefront of revolutionizing drug discovery, ultimately aiming to provide new treatments for currently untreatable diseases.

Digi-Prex is a healthcare company that operates a monthly medication delivery platform focused on chronic disease management. Founded in 2019 and headquartered in Hyderabad, India, with an additional office in San Francisco, California, the company enables patients to manage their conditions more effectively. Digi-Prex provides a subscription service that offers discounted medications based on prescriptions uploaded by patients. The platform ensures regular delivery of these medicines from local pharmacies, making it a cost-effective solution for patients. In addition to medication delivery, Digi-Prex offers a comprehensive service tailored to the unique needs of each patient, creating a one-stop solution for managing chronic health conditions.

Encellin Inc., established in 2016, is a biotechnology company based in San Francisco, California. It specializes in developing innovative thin-film cell encapsulation devices for cell-based therapeutics, aiming to improve the lives of patients with chronic diseases initially focusing on Type 1 diabetes. The company's technology enables encapsulated cells to function as smart molecular factories, providing potential therapeutic solutions.

Hello Heart Inc., established in 2013 and headquartered in Redwood City, California, specializes in developing digital health solutions. Its flagship product is Hello Heart, a mobile application designed to empower individuals to manage their heart health effectively. The app enables users to track their blood pressure and weight, providing real-time personalized tips based on clinical guidelines. Employers can also utilize this platform to proactively manage employee health risks associated with high blood pressure, fostering behavior change and preventing serious health issues.

Tempo designs and develops a home fitness platform with personal guidance to help users in their training sessions. It features live elite trainers who can help users when they make mistakes. It has built-in three-dimensional sensors that track form, counts reps, and recommend weights. It helps users to improve in real-time. Powered by 3D motion sensors and AI, it analyzes 25 of the body’s essential joints as users work out and gives understood form feedback. Moawia Eldeeb and Joshua Augustin founded it as Pivot in 2015, with its headquarters in San Francisco in California.

Cellino is focused on developing a scalable, automated biomanufacturing system aimed at producing personalized cell therapies. The company's innovative platform leverages AI-guided laser editing to generate autologous induced pluripotent stem cells (iPSCs) efficiently and at scale. By utilizing image-guided machine learning, single-cell laser processing, and robotics, Cellino seeks to make advanced, potentially curative treatments accessible for a range of chronic degenerative diseases, including vision loss and Parkinson's disease. The company's mission is to transform healthcare by enabling personalized therapies that can significantly improve patient outcomes and overall health.

Siren Care, Inc. is a San Francisco-based company founded in 2015 that specializes in wearable health technology for diabetic health tracking. The company has developed an innovative product, the Siren diabetic socks, which continuously monitor foot temperature—an early indicator of potential injuries that can lead to ulcers. This smart sock system allows for real-time tracking and sends temperature data to healthcare providers, enabling them to detect early signs of inflammation and other complications in at-risk patients. By engaging with healthcare providers and payers, Siren Care aims to improve the management of chronic diseases, particularly diabetes, and enhance patient outcomes through its comprehensive Siren Diabetic Foot Program.

Carrot Inc. is a company based in Redwood City, California, that specializes in smoking cessation through its application, Pivot. Founded in 2015, Carrot provides a unique six-stage program that engages smokers at an early stage, fostering awareness and confidence without pressuring them to quit. The application assists users in identifying their motivations for quitting and guides them in developing a personalized quit plan. For those ready to make a change, Pivot offers one-on-one coaching support, helping individuals execute their plans and maintain stability in their cessation journey. Through this approach, Carrot aims to support smokers in their transition away from tobacco use.

Higia Technologies, founded in 2016 and based in Mexico City, specializes in developing EVA, a non-invasive wearable device aimed at assessing breast cancer risk. This innovative device features tactile sensors that map the surface of the breast and its surrounding areas. By continuously monitoring changes in breast temperature, size, and weight through embedded biosensors, EVA empowers women to actively track their breast health. The company's focus is on making breast cancer risk assessment more accessible and user-friendly.

Nebula Genomics is a biotechnology company founded in 2016 and based in San Francisco, California. It specializes in human genome sequencing and the creation of a marketplace for genomic and health data aimed at consumers, researchers, and the medical community. The company's mission is to facilitate genomic sequencing and enhance personalized medicine by aggregating a substantial repository of genetic information. Utilizing blockchain technology, Nebula Genomics ensures that consumers retain control over their data and receive compensation for its use. The marketplace enables researchers to analyze rich genetic datasets, which can accelerate drug development and improve the efficiency of clinical trials. Founded by prominent genomics researcher George Church and his associates, Nebula Genomics offers advanced DNA sequencing technology that allows clients to explore all genes and genetic variants in the genome, thereby providing comprehensive insights into individual health.

Scipher Medicine Corporation is a biotechnology company based in Waltham, Massachusetts, that specializes in precision medicine for patients with autoimmune and cardiovascular diseases. The company has developed a molecular technology platform that utilizes blood samples to analyze RNA and predict patient responses to drug therapies. Its primary offerings include PrismDx tests, which identify patients who may not respond to certain medications, ensuring they can be prescribed alternative treatments. Notably, the PrismRA test assesses patients with rheumatoid arthritis to determine their likelihood of responding to anti-TNF therapies, while PrismUC serves a similar purpose for patients with ulcerative colitis. By focusing on the underlying disease biology rather than just symptoms, Scipher Medicine aims to optimize treatment from the outset, potentially reducing the healthcare costs associated with ineffective therapies. Established in 2013 and rebranded in 2015, Scipher Medicine is committed to transforming drug prescription practices and advancing drug development through its innovative approach.

Remedy is a prescriptive chronic care analytics platform employing artificial intelligence to help value-based health systems determine who should get what care, when, how, and by whom to maximize patient health outcomes per dollar spent. We are a design-driven company with core medical AI technology capable of diagnosing disease, catching hidden high-risk diagnoses, and projecting the development of patient’s health into the future. Built around our core AI engine, our first product Remedy Sentinel helps value-based providers identify hidden chronic, co-morbid conditions and intervene by engaging high-risk patients prior to onset. We envision a world where healthcare marries the science of “health” with the art of “care”: scientific, data-driven decision making drives the best outcomes for each individual patient, and frees providers to focus on applying their human touch. Remedy combines novel artificial intelligence algorithms for predictive medical analytics with a healthcare-optimized product development process to give leaders the tools they need to transform their delivery networks and thrive in a value-based care environment. With this approach, Remedy builds a scalable suite of products that, when deployed, learn from experience, and grow into a solution optimized to fit the needs of specific provider groups and the populations they serve. Remedy systematically maximizes the patient health outcome achieved with each dollar spent by using AI to help determine what care is delivered to whom, when it is delivered, where it is delivered, how it is delivered, followed, and supported, and who should deliver it. We not only surface insights, but also build the necessary tools and helps coordinate step-by-step implementation processes to affect real change.

Lumiata Inc. is a company specializing in predictive health analytics tailored for risk-bearing organizations. Founded in 2013 and based in San Mateo, California, Lumiata utilizes a medical graph that systematically organizes and analyzes a vast array of data points, facilitating real-time predictive analytics for hospital networks and insurance carriers. This technology provides insights into symptoms, diagnoses, procedures, and medications, allowing healthcare providers to enhance patient care efficiency. The company's flagship product, The Lumiata Risk Matrix, offers personalized predictions regarding individual health changes and their timeline, grounded in a robust chain of medical reasoning. Lumiata's platform leverages over 120 million patient records, integrating advanced machine learning tools and pre-trained models to support various applications such as underwriting and care management. By combining big data with clinical expertise, Lumiata empowers healthcare organizations to manage risks and costs effectively while ensuring privacy for individual members.

Viome Life Sciences, established in 2016 and headquartered in Bellevue, Washington, specializes in providing comprehensive health insights through its proprietary at-home clinical-grade tests. The company analyzes RNA from stool samples, along with other bodily fluids, to determine the makeup of microbial communities, offering personalized recommendations for diet and lifestyle based on the results. Viome's services aim to empower individuals to track their microbiome health, mitochondrial health, cellular health, and biological age, ultimately aiding in the prevention and reversal of chronic diseases. The company operates as a subsidiary of BlueDot LLC and sells its products through distributors and online channels.

Zebra Medical Vision Ltd. is a developer of an advanced imaging analytics platform that enhances the capabilities of healthcare institutions in diagnosing and managing diseases. Founded in 2014 and based in Shefayim, Israel, the company provides clinicians with tools for identifying patients at risk of various conditions and facilitates improved preventative treatment pathways. Its platform features advanced learning and computer vision diagnostic algorithms, catering to both healthcare providers and machine-learning researchers. Zebra Medical Vision has established strategic collaborations with organizations such as USARAD Holdings and TELUS Ventures, and its products have received FDA clearance for use in hospitals worldwide, including locations in Australia, India, Europe, the U.S., and Latin America. The company is recognized for its role in the AI and machine learning landscape, having raised significant funding to support its innovative solutions in medical imaging.

Curai Health is a virtual care company founded in 2017 by Neal Khosla and Xavier Amatriain, headquartered in Palo Alto. The company specializes in providing affordable primary care through a chat-based interface that integrates artificial intelligence with human clinicians. This approach leverages advanced machine learning tools to streamline patient interactions and enhance diagnostic accuracy. By creating a responsive learning healthcare system, Curai Health aims to make high-quality primary care accessible to everyone, reducing the overall cost of care delivery. The service is available directly to consumers and can also be accessed through enterprise partnerships, emphasizing its commitment to improving healthcare accessibility and affordability.

Siren Care, Inc. is a San Francisco-based company founded in 2015 that specializes in wearable health technology for diabetic health tracking. The company has developed an innovative product, the Siren diabetic socks, which continuously monitor foot temperature—an early indicator of potential injuries that can lead to ulcers. This smart sock system allows for real-time tracking and sends temperature data to healthcare providers, enabling them to detect early signs of inflammation and other complications in at-risk patients. By engaging with healthcare providers and payers, Siren Care aims to improve the management of chronic diseases, particularly diabetes, and enhance patient outcomes through its comprehensive Siren Diabetic Foot Program.

Atomwise, Inc. is a biotechnology company specializing in deep learning artificial intelligence technology for small molecule drug discovery. Based in San Francisco and founded in 2012, the company has developed AtomNet, a pioneering AI platform that facilitates virtual screening of molecules by predicting the binding of small molecules to proteins through a statistical analysis of experimental affinity measurements and protein structures. Atomwise is focused on addressing over 600 unique disease targets and has established collaborations with over 250 partners, including prominent pharmaceutical and biotechnology firms. By leveraging its advanced technology, Atomwise aims to revolutionize the drug discovery process and advance a pipeline of small-molecule drug candidates into preclinical studies. The company was previously known as Chematria, Inc. and rebranded to Atomwise, Inc. in 2015.

Q Bio, Inc., established in 2015, develops a comprehensive health assessment platform that combines advanced non-invasive imaging, genetic testing, vital signs, and medical history to provide a snapshot of an individual's health. The company's flagship product, Q BioVault, aggregates and summarizes an individual's entire medical history, identifying and tracking significant health changes. Q Bio's interdisciplinary team, based in San Carlos, California, comprises experts in applied math, computational physics, electrical engineering, genetics, and radiology. Backed by prominent venture capital firms, the company aims to empower healthcare professionals with proactive, data-driven insights to improve patient outcomes.

Ellipsis Health, Inc. is a technology company based in San Francisco, California, founded in 2013. It specializes in developing innovative analytics solutions that integrate patient speech and clinical data to assess mental health and well-being. By utilizing artificial intelligence, Ellipsis Health aims to enhance behavioral health outcomes through the analysis of natural conversation. The company has created a platform that generates clinical-grade assessments of anxiety and depression severity, as well as sub-clinical evaluations of stress levels. This technology enables healthcare providers to continuously screen their patient populations, offering a cost-effective method to identify conditions such as depression and ensure patients receive timely support.

Lumiata Inc. is a company specializing in predictive health analytics tailored for risk-bearing organizations. Founded in 2013 and based in San Mateo, California, Lumiata utilizes a medical graph that systematically organizes and analyzes a vast array of data points, facilitating real-time predictive analytics for hospital networks and insurance carriers. This technology provides insights into symptoms, diagnoses, procedures, and medications, allowing healthcare providers to enhance patient care efficiency. The company's flagship product, The Lumiata Risk Matrix, offers personalized predictions regarding individual health changes and their timeline, grounded in a robust chain of medical reasoning. Lumiata's platform leverages over 120 million patient records, integrating advanced machine learning tools and pre-trained models to support various applications such as underwriting and care management. By combining big data with clinical expertise, Lumiata empowers healthcare organizations to manage risks and costs effectively while ensuring privacy for individual members.

Deep Genomics Inc. is an artificial intelligence therapeutics company based in Toronto, Canada, founded in 2014. The company focuses on developing individualized genetic medicines by utilizing AI systems to enhance various aspects of drug discovery and development, such as target discovery, lead optimization, toxicity assessment, and innovative trial design. Deep Genomics specializes in creating oligonucleotide therapies that address the genetic underpinnings of diseases at the RNA and DNA levels, targeting rare metabolic, ophthalmologic, and neurodegenerative disorders. Its AI-powered platform decodes the complexities of RNA biology, enabling the identification of novel therapeutic targets and mechanisms that traditional methods cannot access. This innovative approach positions Deep Genomics at the forefront of revolutionizing drug discovery, ultimately aiming to provide new treatments for currently untreatable diseases.

Karius, Inc. is a life sciences company based in Redwood City, California, with an additional office in Menlo Park. Founded in 2014, Karius specializes in generating genomic insights for infectious diseases through its innovative Karius Test. This non-invasive blood test utilizes sequencing of microbial cell-free DNA to identify and quantify a wide range of pathogens, including bacteria, DNA viruses, fungi, and parasites. The Karius Test is particularly useful in the diagnosis of complicated pneumonia, infections in immunocompromised patients, and endocarditis, enabling clinicians to make rapid and informed treatment decisions. Karius operates a CLIA-certified and CAP-accredited laboratory, providing high-complexity clinical laboratory testing and offering services for pathogen biomarker detection aimed at biopharmaceutical companies. The company is dedicated to advancing the understanding and management of infectious diseases, striving for a future where these conditions pose less of a threat to human health.

Viome Life Sciences, established in 2016 and headquartered in Bellevue, Washington, specializes in providing comprehensive health insights through its proprietary at-home clinical-grade tests. The company analyzes RNA from stool samples, along with other bodily fluids, to determine the makeup of microbial communities, offering personalized recommendations for diet and lifestyle based on the results. Viome's services aim to empower individuals to track their microbiome health, mitochondrial health, cellular health, and biological age, ultimately aiding in the prevention and reversal of chronic diseases. The company operates as a subsidiary of BlueDot LLC and sells its products through distributors and online channels.

Guardant Health, Inc. is a precision oncology company headquartered in Redwood City, California, specializing in liquid biopsy tests for cancer diagnosis and treatment. The company provides a range of blood tests, including Guardant360, which measures various cancer-related genes for advanced stage cancer treatment selection, and GuardantOMNI, a broader gene panel that supports immuno-oncology research. Additionally, Guardant Health offers LUNAR-1 for detecting minimal residual disease and recurrence in cancer survivors, along with the development of LUNAR-2 for early cancer detection in high-risk individuals. The company also provides development services such as companion diagnostic development and clinical trial support to biopharmaceutical firms and medical institutions. Founded in 2011, Guardant Health is recognized for its innovative approach to addressing unmet needs in oncology through advanced technology and analytics.

Twine Health, Inc. is a cloud-based software platform focused on chronic care management. Founded in 2012 and based in Cambridge, Massachusetts, Twine Health provides tools for shared decision-making, enabling patients and clinicians to collaboratively set health goals and evaluate management options. Its platform includes self-tracking tools that empower patients to take control of their conditions, dashboards for clinicians to monitor patient progress, and integrated messaging features to facilitate communication. Twine Health also offers a patient engagement portal, a peer support network, and an outcome analytics tool, all designed to foster collaboration among patients, healthcare providers, and support teams such as nurses and health coaches. The platform aims to enhance patient self-efficacy and improve health outcomes through continuous, personalized care.

Ontera Inc. is a biotechnology company focused on developing innovative single molecule detection and genome analysis platforms utilizing biochemistry and silicon nanopore chip technology. Founded in 2011 and based in Santa Cruz, California, Ontera offers a range of products including SAM, a sample-to-answer device applicable across various fields such as agriculture, human diagnostics, and life sciences. This device detects and quantifies a variety of targets, including proteins and small molecules. Additionally, the company provides the DUO Nano platform, designed for genome mapping and sequencing. Ontera’s solutions serve diverse markets, including human and animal diagnostics, agriculture, law enforcement, and drug discovery. The company, formerly known as Two Pore Guys, Inc., rebranded in May 2019 as it aims to enhance point-of-care testing and advance third generation sequencing technologies.

Inflammatix is a molecular diagnostics company based in Burlingame, California, founded in 2016. It specializes in developing rapid tests that analyze the immune system to address significant clinical and public health issues. The company's initial focus is on creating tests for acute bacterial and viral infections, as well as sepsis, utilizing patent-pending biomarkers exclusively licensed from Stanford University. Inflammatix also builds a diagnostics pipeline based on host response, which includes tests for tropical infections, autoimmune diseases, transplant rejection, and other conditions.

PatientBank is a medical information-sharing platform that facilitates the online request and management of medical records from various healthcare providers, including doctors and hospitals. The service enables patients to gather and store their medical records securely, allowing for easy sharing with care providers, hospitals, and family members. By streamlining the process of retrieving and sharing medical information, PatientBank enhances the efficiency of health checkups and improves communication between patients and their healthcare teams. The platform aims to empower individuals in managing their health information, making it more accessible when needed.

Luminostics, Inc. is a Houston-based company that specializes in developing a smartphone-based adaptor designed for rapid, molecular-level health testing. Founded in 2015, Luminostics focuses on providing a 15-minute do-it-yourself disease testing solution that caters to both healthcare professionals and consumers. The technology allows users to access vital health information conveniently and efficiently, streamlining the process of disease detection and management.

AVA, Inc. is a Boston-based company founded in 2016 that offers a messaging-based platform designed to enhance people's relationship with food and nutritional health. The platform enables users to track their food choices, calculate meal calories, and receive personalized meal recommendations. Through dedicated nutritional coaching and user-friendly technology, AVA aims to make it easier for individuals to monitor their dietary habits and adopt healthier eating practices. As of November 2019, AVA operates as a subsidiary of Koninklijke DSM N.V.

Lumiata Inc. is a company specializing in predictive health analytics tailored for risk-bearing organizations. Founded in 2013 and based in San Mateo, California, Lumiata utilizes a medical graph that systematically organizes and analyzes a vast array of data points, facilitating real-time predictive analytics for hospital networks and insurance carriers. This technology provides insights into symptoms, diagnoses, procedures, and medications, allowing healthcare providers to enhance patient care efficiency. The company's flagship product, The Lumiata Risk Matrix, offers personalized predictions regarding individual health changes and their timeline, grounded in a robust chain of medical reasoning. Lumiata's platform leverages over 120 million patient records, integrating advanced machine learning tools and pre-trained models to support various applications such as underwriting and care management. By combining big data with clinical expertise, Lumiata empowers healthcare organizations to manage risks and costs effectively while ensuring privacy for individual members.

Zebra Medical Vision Ltd. is a developer of an advanced imaging analytics platform that enhances the capabilities of healthcare institutions in diagnosing and managing diseases. Founded in 2014 and based in Shefayim, Israel, the company provides clinicians with tools for identifying patients at risk of various conditions and facilitates improved preventative treatment pathways. Its platform features advanced learning and computer vision diagnostic algorithms, catering to both healthcare providers and machine-learning researchers. Zebra Medical Vision has established strategic collaborations with organizations such as USARAD Holdings and TELUS Ventures, and its products have received FDA clearance for use in hospitals worldwide, including locations in Australia, India, Europe, the U.S., and Latin America. The company is recognized for its role in the AI and machine learning landscape, having raised significant funding to support its innovative solutions in medical imaging.

Thync, Inc. is a technology company based in Los Gatos, California, founded in 2011. The company specializes in developing wearable devices that leverage neurosignaling to facilitate transitions between different mental states, such as energy, calm, and focus. Drawing on expertise in neurobiology and neuroscience, Thync creates bioelectronic products aimed at enhancing mental well-being and addressing various consumer needs. Their innovative technology enables users to boost energy levels and improve mental clarity by directly activating specific nerves and neurons through neurostimulation patches. Thync's focus on the intersection of neuroscience and consumer electronics positions it as a pioneer in the field of wearable mental health technology.

Luminist, Inc. is a biomedical company focused on developing a diagnostic platform aimed at the early detection and diagnosis of liver disease. Established in 2015 and located in Newark, California, Luminist operates as a subsidiary of DiscernDx. The company's innovative platform leverages data-driven methodologies to transform biochemical data into essential health information. This enables healthcare providers to deliver comprehensive insights regarding liver diseases and cancer screening through a single diagnostic test, enhancing patient care and facilitating timely medical intervention.

Guardant Health, Inc. is a precision oncology company headquartered in Redwood City, California, specializing in liquid biopsy tests for cancer diagnosis and treatment. The company provides a range of blood tests, including Guardant360, which measures various cancer-related genes for advanced stage cancer treatment selection, and GuardantOMNI, a broader gene panel that supports immuno-oncology research. Additionally, Guardant Health offers LUNAR-1 for detecting minimal residual disease and recurrence in cancer survivors, along with the development of LUNAR-2 for early cancer detection in high-risk individuals. The company also provides development services such as companion diagnostic development and clinical trial support to biopharmaceutical firms and medical institutions. Founded in 2011, Guardant Health is recognized for its innovative approach to addressing unmet needs in oncology through advanced technology and analytics.

Twine Health, Inc. is a cloud-based software platform focused on chronic care management. Founded in 2012 and based in Cambridge, Massachusetts, Twine Health provides tools for shared decision-making, enabling patients and clinicians to collaboratively set health goals and evaluate management options. Its platform includes self-tracking tools that empower patients to take control of their conditions, dashboards for clinicians to monitor patient progress, and integrated messaging features to facilitate communication. Twine Health also offers a patient engagement portal, a peer support network, and an outcome analytics tool, all designed to foster collaboration among patients, healthcare providers, and support teams such as nurses and health coaches. The platform aims to enhance patient self-efficacy and improve health outcomes through continuous, personalized care.

Klarismo Limited is a health technology company based in London, United Kingdom, that specializes in 3D body analysis using magnetic resonance imaging (MRI). Founded in 2014, it offers a platform that converts full-body MRI scans into detailed 3D virtual models, allowing users to explore their body composition with unprecedented precision. The service provides volumetric measurements of muscle and fat tissues, helping health-conscious consumers and amateur athletes understand their physiological changes over time. With regular MRI scans, Klarismo updates users' 3D models to reflect changes in muscle and fat distribution, facilitating effective monitoring of fitness and dietary progress. In addition to serving individual users, the company assists private medical imaging centers in optimizing their resources and builds a database of full-body MRI scans for medical research purposes.

Tempo designs and develops a home fitness platform with personal guidance to help users in their training sessions. It features live elite trainers who can help users when they make mistakes. It has built-in three-dimensional sensors that track form, counts reps, and recommend weights. It helps users to improve in real-time. Powered by 3D motion sensors and AI, it analyzes 25 of the body’s essential joints as users work out and gives understood form feedback. Moawia Eldeeb and Joshua Augustin founded it as Pivot in 2015, with its headquarters in San Francisco in California.

Atomwise, Inc. is a biotechnology company specializing in deep learning artificial intelligence technology for small molecule drug discovery. Based in San Francisco and founded in 2012, the company has developed AtomNet, a pioneering AI platform that facilitates virtual screening of molecules by predicting the binding of small molecules to proteins through a statistical analysis of experimental affinity measurements and protein structures. Atomwise is focused on addressing over 600 unique disease targets and has established collaborations with over 250 partners, including prominent pharmaceutical and biotechnology firms. By leveraging its advanced technology, Atomwise aims to revolutionize the drug discovery process and advance a pipeline of small-molecule drug candidates into preclinical studies. The company was previously known as Chematria, Inc. and rebranded to Atomwise, Inc. in 2015.

Zebra Medical Vision Ltd. is a developer of an advanced imaging analytics platform that enhances the capabilities of healthcare institutions in diagnosing and managing diseases. Founded in 2014 and based in Shefayim, Israel, the company provides clinicians with tools for identifying patients at risk of various conditions and facilitates improved preventative treatment pathways. Its platform features advanced learning and computer vision diagnostic algorithms, catering to both healthcare providers and machine-learning researchers. Zebra Medical Vision has established strategic collaborations with organizations such as USARAD Holdings and TELUS Ventures, and its products have received FDA clearance for use in hospitals worldwide, including locations in Australia, India, Europe, the U.S., and Latin America. The company is recognized for its role in the AI and machine learning landscape, having raised significant funding to support its innovative solutions in medical imaging.

Guardant Health, Inc. is a precision oncology company headquartered in Redwood City, California, specializing in liquid biopsy tests for cancer diagnosis and treatment. The company provides a range of blood tests, including Guardant360, which measures various cancer-related genes for advanced stage cancer treatment selection, and GuardantOMNI, a broader gene panel that supports immuno-oncology research. Additionally, Guardant Health offers LUNAR-1 for detecting minimal residual disease and recurrence in cancer survivors, along with the development of LUNAR-2 for early cancer detection in high-risk individuals. The company also provides development services such as companion diagnostic development and clinical trial support to biopharmaceutical firms and medical institutions. Founded in 2011, Guardant Health is recognized for its innovative approach to addressing unmet needs in oncology through advanced technology and analytics.

DB CyberTech is a cybersecurity company specializing in predictive data loss prevention technologies designed to safeguard business data. Founded in 2009 and headquartered in San Diego, California, the company leverages advanced techniques such as deep protocol extraction, machine learning, and behavioral analysis to assess database infrastructures. Its innovative products enable non-intrusive monitoring and analysis of database activity, allowing organizations to accurately identify insider threats and database attacks. DB CyberTech serves a diverse clientele, including major financial institutions, healthcare providers, manufacturers, and government entities. The company's solutions provide detailed insights into application and database interactions, enhancing situational awareness and helping clients protect sensitive information from potential breaches.

Misfit Wearables, founded in 2011 and headquartered in Burlingame, California, specializes in creating innovative wearable devices aimed at enhancing consumer health and fitness. The company focuses on developing products that encourage users to adopt active lifestyles and cultivate healthy habits. One of its flagship offerings is the Shine, a sleek personal activity tracker that effortlessly syncs with smartphones. As a pioneer in the wearable sensor technology sector, Misfit is dedicated to producing stylish and functional devices that people will want to wear consistently.

Thync, Inc. is a technology company based in Los Gatos, California, founded in 2011. The company specializes in developing wearable devices that leverage neurosignaling to facilitate transitions between different mental states, such as energy, calm, and focus. Drawing on expertise in neurobiology and neuroscience, Thync creates bioelectronic products aimed at enhancing mental well-being and addressing various consumer needs. Their innovative technology enables users to boost energy levels and improve mental clarity by directly activating specific nerves and neurons through neurostimulation patches. Thync's focus on the intersection of neuroscience and consumer electronics positions it as a pioneer in the field of wearable mental health technology.

EyeNetra, Inc. is a company that specializes in developing and manufacturing eye diagnostic tools, including auto-refractors and lens-meters. Founded in 2011 and based in Somerville, Massachusetts, EyeNetra's innovative platform allows users to conduct their own eye tests and obtain refractive measurements for conditions such as nearsightedness, farsightedness, and astigmatism. The company’s products enable eye care professionals to administer efficient eye tests, facilitating quick and accurate diagnoses and prescriptions. Among its offerings is the NETRA autorefractor, which, along with other devices, provides a comprehensive refraction system designed for ease of use and high precision. Additionally, EyeNetra has developed the Insight Portal, enhancing electronic medical record capabilities and providing a streamlined solution for managing patients in mobile clinics globally.